Fri 5/29/2020 14:48 ET
DJIA25250.68148.980.59%TELCO167.591.681.00%GOLD1736.5023.271.34%Shanghai2846.410.280.01%
S&P 5003021.528.160.27%BANKS339.437.092.09%OIL34.981.273.63%BITCOIN9423.14112.141.19%
NASDAQ9402.7533.850.36%PHARM610.620.060.01%US/EU1.110.000.00%Futures3022.3815.720.52%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Keryx Biopharmaceuticals - KERX   

Return Top | Return List | Reply Thread | Search | Add KERX | Ignore KERX
From: SpecGuru (Rep: 63)Date: 2016-09-12 15:09:11
Forum: Keryx Biopharmaceuticals - Thread #673868708Msg #2598 - Part 1/15 (Rec: 0)
Flirting $7.00.

*****I am writing drunk*****

Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2016-09-12 15:11:37
Forum: Keryx Biopharmaceuticals - Thread #673868708Msg #2599 - Part 2/15 (Rec: 0)
I should say it has all short term, intermediate term and long term catalysts. Re: Flirting $7.00.

*****I am writing drunk*****



Reply to SpecGuru - Msg #2636297 - 09/12/2016 15:09
Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2016-09-13 15:27:43
Forum: Keryx Biopharmaceuticals - Thread #673868708Msg #2600 - Part 3/15 (Rec: 0)
Strong in this bloody market. Production resuming, sNDA, IDA filing, Bought-out, etc. coming in the next few months touching $5 Billion market. Expecting double digit market cap.
"...Keryx (NASDAQ:KERX) reported top-line results from its pivotal Phase 3 study that was intended to provide the basis for a label expansion of Auryxia. With these positive results, the company now intends to file a supplemental new drug application in the third quarter of 2016 seeking to expand Auryxia's indication to iron deficiency anemia.
IDA is a common complication of chronic kidney disease. Approximately, 1.6 million people living in the U.S. with stage 3-5 non-dialysis dependent chronic kidney disease (NDD-CKD) suffer from IDA. If Auryxia will be approved for the treatment of IDA in these patients, it would be the only FDA-approved iron treatment in a tablet form available to these patients...."
Re: I should say it has all short term, intermediate term and long term catalysts...

*****I am writing drunk*****

Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2016-09-16 14:57:51
Forum: Keryx Biopharmaceuticals - Thread #673868708Msg #2601 - Part 4/15 (Rec: 0)
Buy up to $7.00 for a double digit gain in 6 months.Re: Strong in this bloody market. Production resuming, sNDA, IDA filing, Bought-o...

*****I am writing drunk*****

Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2016-09-16 15:55:23
Forum: Keryx Biopharmaceuticals - Thread #673868708Msg #2602 - Part 5/15 (Rec: 0)
GO!!!Re: Buy up to $7.00 for a double digit gain in 6 months.Re: Strong in this bloody...

*****I am writing drunk*****



Reply to SpecGuru - Msg #2637117 - 09/16/2016 14:57
Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2016-09-21 15:24:30
Forum: Keryx Biopharmaceuticals - Thread #673868708Msg #2603 - Part 6/15 (Rec: 0)
Not boring, isn't it? :-)Re: GO!!!Re: Buy up to $7.00 for a double digit gain in 6 months.Re: Strong in th...

*****I am writing drunk*****



Reply to SpecGuru - Msg #2637141 - 09/16/2016 15:55
Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2016-09-21 15:27:09
Forum: Keryx Biopharmaceuticals - Thread #673868708Msg #2604 - Part 7/15 (Rec: 0)
Kerx Biopharmaceuticals looks cheaply valued at these levels. The company expanded its sales team to 95 FTEs, up from 60 in 2014. Expect revenue inflecting upwards from here.
The sales team is working closely with clinicians. Even though a supply disruption will hurt Auryxia sales near-term, management is re-calibrating the manufacturing process to restore output. By fourth quarter, supply levels should return to normal.

The payer access should sustain revenue levels. From its presentation at the Biard global healthcare conference, Kerx said:

“On the payer front, we have access now to majority of patients taking phosphate binders across all Part D and commercials and we continue to see very good pay claim rates at pharmacies when patients still in pharmacy with prescription of Auryxia, the vast majority of those patients are getting that still for $110.”

Kerx may potentially expand Auryxia’s reach in the marketplace. By addressing iron deficiencies for patients, Kerx’s market may more than double.

Catalyst ahead

In the fourth quarter, Kerx has a potential catalyst. A successful application for making the drug available to dialysis patients would boost the stock price. Expanding the indications for the treatment of iron deficiency anaemia is possible. Its success is based on results for its Phase 3 trial completed earlier this year. Re: Not boring, isn't it? :-)Re: GO!!!Re: Buy up to $7.00 for a double digit gain...

*****I am writing drunk*****



Reply to SpecGuru - Msg #2637800 - 09/21/2016 15:24
Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2016-09-21 15:30:37
Forum: Keryx Biopharmaceuticals - Thread #673868708Msg #2605 - Part 8/15 (Rec: 0)
This will be the third presentation this month. Company is working hard! BOSTON , Sept. 21, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc , (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast its corporate presentation at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27 at 4:00 p.m. Eastern Time .
A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals , with headquarters in Boston , is focused on bringing innovative medicines to people with renal disease. In December 2014 , the company launched its first FDA -approved medicine, Auryxia® (ferric citrate) in the United States. In January 2014 , ferric citrate was approved for use in Japan , where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015 , the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). For more information about Keryx, please visit www.keryx.com.
Re: From Chris Lau in Valuestocks "...Kerx Biopharmaceuticals Will Rebound,

*****I am writing drunk*****



Reply to SpecGuru - Msg #2637803 - 09/21/2016 15:27
Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2016-09-22 15:51:29
Forum: Keryx Biopharmaceuticals - Thread #673868708Msg #2606 - Part 9/15 (Rec: 0)
Enjoying? ^^ The problem for shorts is they must compete with each other and the pipe is not wide enough not to cause squeezes. I expect $7 soon, maybe at the announcement of a simple "problem solved!" which "will" be solved anyway in the next two months. Re: This will be the third presentation this month. Company is working hard! BOS...

*****I am writing drunk*****

Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore

From: SpecGuru (Rep: 63) reply to SpecGuruDate: 2016-09-22 15:53:24
Forum: Keryx Biopharmaceuticals - Thread #673868708Msg #2607 - Part 10/15 (Rec: 0)
http://seekingalpha.com/article/4002315-keryx-biopharmaceuticals-highly-asymmetric-bet-long-term-investor Re: Enjoying? :^ The problem for shorts is they must compete with each other and ...

*****I am writing drunk*****

Message: Endorse | Reply | Privately | Bookmark | Report Abuse User SpecGuru: Reward | Watch | Ignore


TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.